Becton, Dickinson and Company (BDX): Price and Financial Metrics
Becton, Dickinson and Company (BDX)
Today's Latest Price: $241.09 USD
Updated Oct 22 4:00pm
Add BDX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BDX Stock Summary
- Becton Dickinson & Co's market capitalization of $68,524,925,456 is ahead of 97.2% of US-listed equities.
- BDX's went public 34.83 years ago, making it older than 92.9% of listed US stocks we're tracking.
- In terms of volatility of its share price, BDX is more volatile than only 2.31% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Becton Dickinson & Co are ZTS, BSX, SYK, MELI, and ABB.
- BDX's SEC filings can be seen here. And to visit Becton Dickinson & Co's official web site, go to www.bd.com.
BDX Stock Price Chart Interactive Chart >
BDX Price/Volume Stats
| Current price | $241.09 | 52-week high | $286.72 |
| Prev. close | $236.40 | 52-week low | $197.75 |
| Day low | $235.48 | Volume | 1,096,090 |
| Day high | $241.42 | Avg. volume | 1,914,712 |
| 50-day MA | $238.98 | Dividend yield | 1.34% |
| 200-day MA | $248.96 | Market Cap | 69.88B |
Becton, Dickinson and Company (BDX) Company Bio
Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $241.09 | $163.04 | -31% |
We started the process of determining a valid price forecast for Becton Dickinson & Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Becton Dickinson & Co ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Becton Dickinson & Co, consider:
- As a business, BDX is generating more cash flow than 87.45% of positive cash flow stocks in the Healthcare.
- Becton Dickinson & Co's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 22.65% of tickers in our DCF set.
- Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -32% |
| 1% | -32% |
| 2% | -31% |
| 3% | -30% |
| 4% | -30% |
| 5% | -29% |
Want more companies with a valuation profile/forecast similar to that of Becton Dickinson & Co? See DGX, EBS, ICLR, RSCF, and STE.
Loading social stream, please wait...